GlassScriptPhysician profile
Robert N Brackenrich
NPI 1215559687
$3,439.54
in general payments reported to CMS, 2019-2025
25 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $170 · 2024: $1,691 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $443.78 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $433.02 | 2024-2025 | |
| Novo Nordisk INC | $418.96 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $319.62 | 2023-2025 | Airsupra, Farxiga |
| Abbvie INC. | $296.22 | 2024-2025 | |
| Glaxosmithkline, LLC. | $204.74 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $183.54 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $144.09 | 2023-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.06 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.88 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $101.24 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $87.53 | 2024-2025 | Rexulti |
| Radius Health, INC. | $84.08 | 2023-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $77.76 | 2024 | Spravato |
| Esperion Therapeutics, INC. | $74.77 | 2024-2025 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.44 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $61.41 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $45.06 | 2024 | Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $32.18 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.00 | 2025 | Voquezna |
| Seqirus USA INC | $25.09 | 2025 | Fluad, Flucelvax |
| Boston Scientific Corporation | $21.50 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $21.38 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $17.64 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $13.55 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brackenrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.